Expression of Bcl-2 in olfactory neuroblastoma and its association with chemotherapy and survival

被引:22
|
作者
Kim, Jeong-Whun [2 ]
Kong, Il Gyu [2 ]
Lee, Chul Hee [2 ]
Kim, Dong Young [2 ]
Rhee, Chae-Seo [2 ]
Min, Yang-Gi [2 ]
Kim, Chul Woo [1 ]
Chung, Jin-Haeng [1 ]
机构
[1] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Pathol, Songnam 463707, Gyeonggi, South Korea
[2] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Otorhinolaryngol, Songnam 463707, Gyeonggi, South Korea
关键词
D O I
10.1016/j.otohns.2008.03.011
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
OBJECTIVE: This study aimed to identify the prognostic value of tumor markers in olfactory neuroblastoma (ONB). STUDY DESIGN AND SETTING: Seventeen patients with ONB (23 tumor specimens) were included. Each specimen was studied for bcl-2, p53, MIC-2 by immunohistochemistry and for N-myc by chromogenic in situ hybridization. RESULTS: Twelve (70%) of 17 patients and 15 (65%) of 23 specimens showed positive reactivity for bcl-2. Of seven patients who were treated with neoadjuvant chemotherapy, one patient with diffuse bcl-2 expression achieved complete remission. Another patient without bcl-2 expression had no response to chemotherapy. Five patients who showed partial positivity achieved partial remission. Survival and bcl-2 expression tended to correlate, but it was not statistically significant (P = 0.06). All of the ONB specimens were negative for N-myc. Positive immunoreactivity for MIC-2 or p53 was found only in one specimen. CONCLUSION: Bcl-2 expression was commonly found in ONB and the immunoreactivity for bcl-2 might predict response to neoadjuvant chemotherapy. In addition. Bcl-2 expression tended to be associated with worse survival. (C) 2008 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved.
引用
收藏
页码:708 / 712
页数:5
相关论文
共 50 条
  • [21] THE BCL-2 ONCOGENE IS A NOVEL PROGNOSTIC MARKER FOR NEUROBLASTOMA AND CONFERS RESISTANCE TO CHEMOTHERAPY
    NUNEZ, G
    DOLE, MG
    HEIDELBERGER, KP
    CASTLE, VP
    LABORATORY INVESTIGATION, 1994, 70 (01) : A147 - A147
  • [22] DEREGULATED EXPRESSION OF BCL-2 CONFERS CHEMOTHERAPY RESISTANCE TO THE NEUROBLASTOMA CELL-LINE SHEP-1
    DOLE, M
    NUNEZ, G
    CASTLE, VP
    CLINICAL RESEARCH, 1993, 41 (03): : A625 - A625
  • [23] Bcl-2 expression mediated by Cre/loxP system in olfactory epithelium
    Doi, Kiyoshi
    Nibu, Ken-ichi
    Okado, Haruo
    Terashima, Toshio
    NEUROSCIENCE LETTERS, 2006, 399 (1-2) : 67 - 70
  • [24] Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma
    Tanos, Rachel
    Karmali, Dipan
    Nalluri, Srilatha
    Goldsmith, Kelly C.
    BMC CANCER, 2016, 16
  • [25] Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma
    Rachel Tanos
    Dipan Karmali
    Srilatha Nalluri
    Kelly C. Goldsmith
    BMC Cancer, 16
  • [26] RELATIONSHIP BETWEEN BCL-2 AND MYC GENE-EXPRESSION IN HUMAN NEUROBLASTOMA
    IKEGAKI, N
    KATSUMATA, M
    TSUJIMOTO, Y
    NAKAGAWARA, A
    BRODEUR, GM
    CANCER LETTERS, 1995, 91 (02) : 161 - 168
  • [27] CELLULAR DEATH IN NEUROBLASTOMA - IN-SITU CORRELATION OF APOPTOSIS AND BCL-2 EXPRESSION
    HOEHNER, JC
    HEDBORG, F
    WIKLUND, HJ
    OLSEN, L
    PAHLMAN, S
    INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (01) : 19 - 24
  • [28] Bcl-2 expression as a prognostic factor of survival of gastric carcinoma
    Inada, T
    Kikuyama, S
    Ichikawa, A
    Igarashi, S
    Ogata, Y
    ANTICANCER RESEARCH, 1998, 18 (3B) : 2003 - 2010
  • [29] VEGF upregulates BCL-2 expression and is associated with decreased apoptosis in neuroblastoma cells
    Beierle, EA
    Strande, LF
    Chen, MK
    JOURNAL OF PEDIATRIC SURGERY, 2002, 37 (03) : 467 - 471
  • [30] PTEN expression in melanoma: Relationship with patient survival, Bcl-2 expression, and proliferation
    Mikhail, M
    Velazquez, E
    Shapiro, R
    Berman, R
    Pavlick, A
    Sorhaindo, L
    Spira, J
    Mir, C
    Panageas, KS
    Polsky, D
    Osman, I
    CLINICAL CANCER RESEARCH, 2005, 11 (14) : 5153 - 5157